[HTML][HTML] TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin
The antifungal, immunosuppressive compound rapamycin arrests the cell cycle in G 1 in
both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in
three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and
genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin.
Consistent with this model, we find that modulating TOR1 and TOR2 expression alters
rapamycin sensitivity. We describe several TOR2 mutations that confer rapamycin …
both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in
three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and
genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin.
Consistent with this model, we find that modulating TOR1 and TOR2 expression alters
rapamycin sensitivity. We describe several TOR2 mutations that confer rapamycin …